Huynh of RBC Capital agreed, citing a survey by his firm of about 200 patients, payers, and prescribers: Our recent survey indicated that Foundayo would be a preferred oral option amongst patients since it has no dosing restrictions. Not so, Novo Nordisk CEO Maziar (Mike) Doustdar told CNBC last month: People are really interested because its the most efficacious pill right now in the market. Novo Nordisk cites efficacy Novo Nordisk sought to reinforce that message via an announcement trumpeting that its 25 mg dose of oral Wegovy showed significantly greater mean weight loss than the 36 mg dose of Foundayo, according to a population-adjusted indirect treatment comparison using data from two clinical trials: OASIS 4 (NCT05564117), a 307-patient randomized study which evaluated once-daily oral Wegovy 25 mg in overweight or obese adults with at least one self-reported unsuccessful dietary effort to lose body weight, to measure their percentage change in body weight and whether it was 5% at the end of treatment at week 64

Available at CVS, Walgreens, Walmart, Target, Amazon , and virtually every pharmacy and grocery store
The arrival of the GLP-1 receptor agonists, especially Wegovy, marked an inflection point for the obesity market, because for the first time pharmacological interventions delivered meaningful weight loss of 10-15%
All of this is to say, patients and physicians are being driven to GLP-1s, particularly semaglutide, for managing obesity
Semi-quantitative analysis was performed for five fields per section in high-power fields at 400 magnification using ImageJ software version 64 (National Institutes of Health)